The Migraine Specific Quality of Life (MSQoL) is a patient-reported outcome measure (PRO or PROM) which assesses the quality of life of migraineurs.[1] It is a 25-item[2] questionnaire which is filled out by the patient and is used to determine how the patient's life has been affected by their migraines.

History and development

The MSQoL was funded by the Wellcome Foundation and developed by Galen Research, as part of an international research study which was conducted in eight countries, with initial work conducted in the UK and US.[3] In the UK, 30 patients who suffer from migraine were interviewed, while 25 patients were interviewed in the US. A focus group was also held with 5 participants. Transcripts of these interviews were used to determine the questionnaire items. The MSQoL was assessed for reliability and validity and was found to have good consistency and test-retest reliability.[4] Scores on the MSQoL were also found to be consistent with another measure of well-being as well as the perceived severity of the affliction for the patients.

International use

The MSQoL has been translated into several languages other than UK English: German, Dutch,[5] Danish, Spanish, Finnish, French,[6] Italian, and USA English.[7]

The MSQoL has also been utilized by pharmaceutical companies in order to test whether a given therapy or medication is effective in treating migraines. The MSQoL has been used in the assessment of the effect of nadolol and topiramate,[8] regular water intake[9] and using migraine patients as trainers in preventive attack management.[10] Different scores on the MSQoL taken before and after the trial infer a change in the patient's quality of life.

References

  1. ↑ McKenna, S.P; Doward, L.C.; Davey, K.M. (1998). "The Development and Psychometric Properties of the MSQOL: A Migraine-Specific Quality-of-Life Instrument". Clinical Drug Investigation. 15 (5): 413–423. doi:10.2165/00044011-199815050-00006. PMID 18370497. S2CID 19903412.
  2. ↑ Wagner, T.H.; Patrick, D.L.; Galer, B.S.; Berzon, R.A. (September 1996). "A New Instrument to Assess the Long-term Quality of Life Effects From Migraine: Development and Psychometric Testing of the MSQOL". Headache: The Journal of Head and Face Pain. 36 (8): 484–492. doi:10.1046/j.1526-4610.1996.3608484.x. PMID 8824004. S2CID 5694914.
  3. ↑ Patrick, Donald L.; Hurst, Bryan C.; Hughes, Janette (July 2000). "Further Development and Testing of the Migraine-Specific Quality of Life (MSQOL) Measure". Headache: The Journal of Head and Face Pain. 40 (7): 550–560. doi:10.1046/j.1526-4610.2000.00086.x. PMID 10940093. S2CID 23808987.
  4. ↑ Wagner, T.H.; Patrick, D.L.; Galer, B.S.; Berzon, R.A. (1996). "A New Instrument to Assess the Long-term Quality of Life Effects From Migraine: Development and Psychometric Testing of the MSQOL". Headache: The Journal of Head and Face Pain. 36 (8): 484–492. doi:10.1046/j.1526-4610.1996.3608484.x. PMID 8824004. S2CID 5694914.
  5. ↑ Passchier J.; Mourik J.; McKenna S.; Van Den Berg M.; Erdman R. (2001). "Evaluation of the Dutch version of the migraine quality of life instrument (MSQOL) and its application in headache coping". Cephalalgia. 21 (8): 823–829. doi:10.1046/j.0333-1024.2001.00237.x. PMID 11737008. S2CID 12083995.
  6. ↑ Gerbaud, L; Navez, ML; Couratier, P; Lejeune, ML; Vernay, D; Aufauvre, D; Preux, PM; Metz, O; Dazord, A; Laurent, B; Clavelou, P (July 2002). "Validation of the combined SF36/MSQOL test of evaluation of quality of life in migraine patients in France". Revue Neurologique. 158 (6–7): 719–727. PMID 12486902.
  7. ↑ "MSQoL". Galen Research.
  8. ↑ Garcia-Monco, JC; Foncea, N; Bilbao, A; Ruiz de Velasco, I; Gomez-Beldarrain, M (August 2007). "Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients". Cephalalgia. 27 (8): 920–928. doi:10.1111/j.1468-2982.2007.01367.x. PMID 17645757. S2CID 9406164.
  9. ↑ Spigt, Mark; Weerkamp, Nico; Troost, Jaap; van Schayck, Constant P; Knottnerus, J Andre (2011). "A randomized trial on the effects of regular water intake in patients with recurrent headaches". Family Practice. 29 (4): 1–6. doi:10.1093/fampra/cmr112. PMID 22113647.
  10. ↑ Merelle, SYM; Sorbi, MJ; Van Doornen, LJP; Passchier, J (February 2008). "Migraine patients as trainers of their fellow patients in non-pharmacological preventive attack management: short-term effects of a randomized controlled trial". Cephalalgia. 28 (2): 127–138. doi:10.1111/j.1468-2982.2007.01472.x. PMID 18197883. S2CID 44246726. Retrieved 8 October 2013.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.